Reply of the Authors: Testosterone therapy and breast cancer?

Leslie R. Schover

doi:10.1016/j.fertnstert.2008.05.063

Reply of the Authors: Testosterone therapy and breast cancer?

Leslie R. Schover

Behavioral Science

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	468-469
Number of pages	2
Journal	Fertility and sterility
Volume	90
Issue number	2
DOIs	https://doi.org/10.1016/j.fertnstert.2008.05.063
State	Published - Aug 2008

ASJC Scopus subject areas

Reproductive Medicine
Obstetrics and Gynecology

Access to Document

10.1016/j.fertnstert.2008.05.063

Cite this

@article{57bbce882f4f446697f814cafd7004b3,

title = "Reply of the Authors: Testosterone therapy and breast cancer?",

author = "Schover, {Leslie R.}",

note = "Funding Information: Dr. Guay's declared conflicts of interests in recent publications confirm that he has had research grants or participated in protocols funded by Auxilium, BioSante, Solvay, Vivus, and Cellegy and has been an advisor or consultant to Solvay, Auxilium, and Cellegy—all companies developing T products to treat female sexual dysfunction. Dr. Traish has had grants from the National Institutes of Health. I could not find evidence on whether he has had Pharma funding. The stakes are high, however. With increasing competition for shrinking federal research grants, BioSante will spend an estimated 12 million dollars on research in 2008 hoping to win FDA approval for its T gel for women, estimating that annual sales will exceed $500 million (4) . ",

year = "2008",

month = aug,

doi = "10.1016/j.fertnstert.2008.05.063",

language = "English (US)",

volume = "90",

pages = "468--469",

journal = "Fertility and sterility",

issn = "0015-0282",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Reply of the Authors

T2 - Testosterone therapy and breast cancer?

AU - Schover, Leslie R.

N1 - Funding Information: Dr. Guay's declared conflicts of interests in recent publications confirm that he has had research grants or participated in protocols funded by Auxilium, BioSante, Solvay, Vivus, and Cellegy and has been an advisor or consultant to Solvay, Auxilium, and Cellegy—all companies developing T products to treat female sexual dysfunction. Dr. Traish has had grants from the National Institutes of Health. I could not find evidence on whether he has had Pharma funding. The stakes are high, however. With increasing competition for shrinking federal research grants, BioSante will spend an estimated 12 million dollars on research in 2008 hoping to win FDA approval for its T gel for women, estimating that annual sales will exceed $500 million (4) .

PY - 2008/8

Y1 - 2008/8

UR - http://www.scopus.com/inward/record.url?scp=47849084296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47849084296&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2008.05.063

DO - 10.1016/j.fertnstert.2008.05.063

M3 - Letter

AN - SCOPUS:47849084296

SN - 0015-0282

VL - 90

SP - 468

EP - 469

JO - Fertility and sterility

JF - Fertility and sterility

IS - 2

ER -

Reply of the Authors: Testosterone therapy and breast cancer?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this